APA

Krebs M., Solimando A. G., Kalogirou C., Marquardt A., Frank T., Sokolakis I., Hatzichristodoulou G., Kneitz S., Bargou R., Kübler H., Schilling B., Spahn M. & Kneitz B. (2020). miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. : Journal of clinical medicine.

Chicago

Krebs Markus, Solimando Antonio Giovanni, Kalogirou Charis, Marquardt André, Frank Torsten, Sokolakis Ioannis, Hatzichristodoulou Georgios, Kneitz Susanne, Bargou Ralf, Kübler Hubert, Schilling Bastian, Spahn Martin and Kneitz Burkhard. 2020. miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. : Journal of clinical medicine.

Harvard

Krebs M., Solimando A. G., Kalogirou C., Marquardt A., Frank T., Sokolakis I., Hatzichristodoulou G., Kneitz S., Bargou R., Kübler H., Schilling B., Spahn M. and Kneitz B. (2020). miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. : Journal of clinical medicine.

MLA

Krebs Markus, Solimando Antonio Giovanni, Kalogirou Charis, Marquardt André, Frank Torsten, Sokolakis Ioannis, Hatzichristodoulou Georgios, Kneitz Susanne, Bargou Ralf, Kübler Hubert, Schilling Bastian, Spahn Martin and Kneitz Burkhard. miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. : Journal of clinical medicine. 2020.